TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Delayed Deutsche Boerse AG 12:02:15 2024-07-01 EDT | ||
| 4.05 EUR | -4.71% |
|
| Current month | -39.89% | ||
| 1 month | -38.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 4.05 | -4.71% |
| 24-06-28 | 4.25 | -9.96% |
| 24-06-27 | 4.72 | -3.08% |
| 24-06-26 | 4.87 | -4.32% |
| 24-06-25 | 5.09 | -1.17% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 12:02 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88XV |
| ISIN | DE000SW88XV4 |
| Date issued | 2024-04-19 |
| Strike | 1,442 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 8.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.88 € |
|---|---|
| Lowest since issue | 4.05 € |
| Spread | 0.24 € |
| Spread % | 5.73% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
